Biogen Digital Health
Our Portfolio
Our Digital Health Solutions
Our portfolio of digital health solutions includes initiatives across clinical development and real-world settings in various stages (development, validation, and in-market) and different therapeutic areas.
We focus on three main categories: digital health solutions, digital medicine solutions, and digital therapeutics.
Digital Health
Digital health solutions include technologies, platforms, and systems that engage consumers for lifestyle, wellness, and health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations.
Cleo/Aby
Stage: In-Market
Digital care companion smartphone app to help people better live with MS
Cleo/Aby provides information, tips, symptom-tracking, reminders, and tailored programs for self-care with the goal of improving the daily lives of people living with MS and their caregivers.
Physio.me
Stage: Validation
Digital exercise platform that offers at-home, tailored programs for people living with neuromuscular diseases.
With Physio.me, the physiotherapist defines a tailored program adapted to the patient’s specific goals. The patient can then perform exercises from the comfort of their own home.
Neurodiem
Stage: In-Market
Website for healthcare professionals to stay informed about the latest developments in neuroscience
Neurodiem is an independent information and education platform with over 10,000 pieces of scientifically validated content to help healthcare professionals remain at the forefront in neuroscience.
Neurodiem is available in 30 countries and nine languages.
Digital Medicine
Digital medicine solutions include evidence-based software and/or hardware products that measure and/or intervene in the service of human health (e.g., digital biomarkers and remote patient monitoring).
Capsule
Stage: Validation
Virtual reality (VR) solution to improve neuromuscular disease patients’ experience during medical procedures
Capsule leverages an evidence-based Class I medical device that combines immersion through VR technology and medical hypnosis.
Konectom
Stage: Validation
Patient-centric digital biomarker platform to assess neurological functions remotely for more precise, frequent measurement of disease evolution
Konectom seeks to support real-world evidence and enable R&D decisions with sensitive and predictive measures of disease progression. It uses scientifically validated active and passive assessment modules leveraging smartphone sensors to assess cognition, fine motor control, mobility, quality of life, and other domains in-clinic or remotely.
MS Lesion Analyzer (In collaboration with Therapanacea)
Stage: Development
Classifier leveraging machine learning to potentially predict lesion age and serve as a prognostic tool for future disease activity
MS Lesion Analyzer aims to help unlock insights about underlying disease processes previously unseen to the human eye. This solution is intended to enable personalized and earlier treatment decisions in MS.
Digital Therapeutics
Digital therapeutics (DTx) aim to deliver evidence-based therapeutic interventions to prevent, manage, or treat a medical disorder or disease.
MR-004 (In collaboration with MedRhythms)
Stage: Development
Walking disability, a common symptom of MS, significantly decreases independence, reduces quality of life, and increases falls. Research has shown that music-based rhythmic auditory stimulation (RAS) can improve walking speed, stride length, and symmetry, and even reduce falls.
MR-004 combines sensors, software, and music to target neural circuitry. The study plans to test a course of therapy of three 30-minute sessions per week for three months.